Do analysts rate HOWL or RDHL?

Werewolf Therapeutics presently has a consensus target price of $3.75, indicating a potential upside of 778.22%. Given Werewolf Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Werewolf Therapeutics is more favorable than Redhill Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Werewolf Therapeutics 1 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.14 Redhill Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is HOWL or RDHL more profitable?

Redhill Biopharma's return on equity of 0.00% beat Werewolf Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Werewolf Therapeutics N/A -208.23% -75.12% Redhill Biopharma N/A N/A N/A

Does the media favor HOWL or RDHL?

In the previous week, Redhill Biopharma had 1 more articles in the media than Werewolf Therapeutics. MarketBeat recorded 3 mentions for Redhill Biopharma and 2 mentions for Werewolf Therapeutics. Redhill Biopharma's average media sentiment score of 1.29 beat Werewolf Therapeutics' score of 0.94 indicating that Redhill Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Werewolf Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Redhill Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate CYCN or RDHL?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cyclerion Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Redhill Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate AIMD or RDHL?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ainos 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Redhill Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, AIMD or RDHL?

Redhill Biopharma has higher revenue and earnings than Ainos. Ainos is trading at a lower price-to-earnings ratio than Redhill Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ainos $18.11K 658.91 -$14.77M -$2.89 N/A Redhill Biopharma $290K 13.28 -$430K $900.00 0.00

Is AIMD or RDHL more profitable?

Redhill Biopharma has a net margin of 0.00% compared to Ainos' net margin of -11,912.10%. Redhill Biopharma's return on equity of 0.00% beat Ainos' return on equity. Company Net Margins Return on Equity Return on Assets Ainos -11,912.10% -160.55% -62.29% Redhill Biopharma N/A N/A N/A

Do analysts recommend RDHL or APLT?

Applied Therapeutics has a consensus target price of $1.00, suggesting a potential upside of 870.87%. Given Applied Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Applied Therapeutics is more favorable than Redhill Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Redhill Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Applied Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Is RDHL or APLT more profitable?

Redhill Biopharma's return on equity of 0.00% beat Applied Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Redhill Biopharma N/A N/A N/A Applied Therapeutics N/A -340.84% -175.00%

Do analysts prefer TPST or RDHL?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tempest Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Redhill Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is TPST or RDHL more profitable?

Redhill Biopharma's return on equity of 0.00% beat Tempest Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Tempest Therapeutics N/A -355.61% -121.21% Redhill Biopharma N/A N/A N/A

Does the media favor TPST or RDHL?

In the previous week, Tempest Therapeutics had 1 more articles in the media than Redhill Biopharma. MarketBeat recorded 4 mentions for Tempest Therapeutics and 3 mentions for Redhill Biopharma. Redhill Biopharma's average media sentiment score of 1.29 beat Tempest Therapeutics' score of 0.97 indicating that Redhill Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tempest Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Redhill Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Redhill Biopharma (RDHL) Competitors

$0.63 -0.03 (-5.22%)

Closing price 07/24/2026 03:59 PM Eastern

Extended Trading

$0.65 +0.02 (+2.64%)

As of 07/24/2026 05:27 PM Eastern

Compare

RDHL vs. HOWL, CYCN, AIMD, APLT, and TPST

Should you buy Redhill Biopharma stock or one of its competitors? MarketBeat compares Redhill Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Redhill Biopharma include Werewolf Therapeutics (HOWL), Cyclerion Therapeutics (CYCN), Ainos (AIMD), Applied Therapeutics (APLT), and Tempest Therapeutics (TPST). These companies are all part of the "pharmaceutical products" industry.

How does Redhill Biopharma compare to Werewolf Therapeutics?

Werewolf Therapeutics (NASDAQ:HOWL) and Redhill Biopharma (NASDAQ:RDHL) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, risk, earnings, profitability, dividends, valuation and analyst recommendations.

Werewolf Therapeutics has a beta of 0.3, indicating that its stock price is 70% less volatile than the broader market. Comparatively, Redhill Biopharma has a beta of 4.98, indicating that its stock price is 398% more volatile than the broader market.

Redhill Biopharma has higher revenue and earnings than Werewolf Therapeutics. Werewolf Therapeutics is trading at a lower price-to-earnings ratio than Redhill Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Werewolf Therapeutics	N/A	N/A	-$60.82M	-$1.24	N/A
Redhill Biopharma	$290K	13.28	-$430K	$900.00	0.00

64.8% of Werewolf Therapeutics shares are owned by institutional investors. Comparatively, 7.2% of Redhill Biopharma shares are owned by institutional investors. 23.6% of Werewolf Therapeutics shares are owned by company insiders. Comparatively, 6.8% of Redhill Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Redhill Biopharma's return on equity of 0.00% beat Werewolf Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Werewolf Therapeutics	N/A	-208.23%	-75.12%
Redhill Biopharma	N/A	N/A	N/A

Werewolf Therapeutics presently has a consensus target price of $3.75, indicating a potential upside of 778.22%. Given Werewolf Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Werewolf Therapeutics is more favorable than Redhill Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Werewolf Therapeutics	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
Redhill Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Redhill Biopharma had 1 more articles in the media than Werewolf Therapeutics. MarketBeat recorded 3 mentions for Redhill Biopharma and 2 mentions for Werewolf Therapeutics. Redhill Biopharma's average media sentiment score of 1.29 beat Werewolf Therapeutics' score of 0.94 indicating that Redhill Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Werewolf Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Redhill Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Redhill Biopharma beats Werewolf Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Redhill Biopharma compare to Cyclerion Therapeutics?

Cyclerion Therapeutics (NASDAQ:CYCN) and Redhill Biopharma (NASDAQ:RDHL) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability, media sentiment and analyst recommendations.

In the previous week, Redhill Biopharma had 2 more articles in the media than Cyclerion Therapeutics. MarketBeat recorded 3 mentions for Redhill Biopharma and 1 mentions for Cyclerion Therapeutics. Cyclerion Therapeutics' average media sentiment score of 1.89 beat Redhill Biopharma's score of 1.29 indicating that Cyclerion Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Cyclerion Therapeutics	Very Positive
Redhill Biopharma	Positive

Cyclerion Therapeutics has a beta of 1.74, indicating that its share price is 74% more volatile than the broader market. Comparatively, Redhill Biopharma has a beta of 4.98, indicating that its share price is 398% more volatile than the broader market.

Redhill Biopharma has a net margin of 0.00% compared to Cyclerion Therapeutics' net margin of -170.11%. Redhill Biopharma's return on equity of 0.00% beat Cyclerion Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cyclerion Therapeutics	-170.11%	-62.10%	-55.14%
Redhill Biopharma	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cyclerion Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Redhill Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

75.6% of Cyclerion Therapeutics shares are owned by institutional investors. Comparatively, 7.2% of Redhill Biopharma shares are owned by institutional investors. 34.3% of Cyclerion Therapeutics shares are owned by company insiders. Comparatively, 6.8% of Redhill Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Redhill Biopharma has lower revenue, but higher earnings than Cyclerion Therapeutics. Cyclerion Therapeutics is trading at a lower price-to-earnings ratio than Redhill Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cyclerion Therapeutics	$1.99M	7.60	-$3.53M	-$1.36	N/A
Redhill Biopharma	$290K	13.28	-$430K	$900.00	0.00

Summary

Redhill Biopharma beats Cyclerion Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Redhill Biopharma compare to Ainos?

Ainos (NASDAQ:AIMD) and Redhill Biopharma (NASDAQ:RDHL) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends.

7.2% of Redhill Biopharma shares are owned by institutional investors. 9.8% of Ainos shares are owned by insiders. Comparatively, 6.8% of Redhill Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Redhill Biopharma has higher revenue and earnings than Ainos. Ainos is trading at a lower price-to-earnings ratio than Redhill Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ainos	$18.11K	658.91	-$14.77M	-$2.89	N/A
Redhill Biopharma	$290K	13.28	-$430K	$900.00	0.00

In the previous week, Redhill Biopharma had 2 more articles in the media than Ainos. MarketBeat recorded 3 mentions for Redhill Biopharma and 1 mentions for Ainos. Redhill Biopharma's average media sentiment score of 1.29 beat Ainos' score of 0.94 indicating that Redhill Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Ainos	Positive
Redhill Biopharma	Positive

Ainos has a beta of 2.43, indicating that its share price is 143% more volatile than the broader market. Comparatively, Redhill Biopharma has a beta of 4.98, indicating that its share price is 398% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ainos	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Redhill Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Redhill Biopharma has a net margin of 0.00% compared to Ainos' net margin of -11,912.10%. Redhill Biopharma's return on equity of 0.00% beat Ainos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ainos	-11,912.10%	-160.55%	-62.29%
Redhill Biopharma	N/A	N/A	N/A

Summary

Redhill Biopharma beats Ainos on 11 of the 13 factors compared between the two stocks.

How does Redhill Biopharma compare to Applied Therapeutics?

Redhill Biopharma (NASDAQ:RDHL) and Applied Therapeutics (NASDAQ:APLT) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, earnings, profitability, media sentiment and institutional ownership.

Redhill Biopharma has higher earnings, but lower revenue than Applied Therapeutics. Applied Therapeutics is trading at a lower price-to-earnings ratio than Redhill Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Redhill Biopharma	$290K	13.28	-$430K	$900.00	0.00
Applied Therapeutics	$1M	15.86	-$105.62M	-$0.10	N/A

Applied Therapeutics has a consensus target price of $1.00, suggesting a potential upside of 870.87%. Given Applied Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Applied Therapeutics is more favorable than Redhill Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Redhill Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Applied Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

In the previous week, Redhill Biopharma had 3 more articles in the media than Applied Therapeutics. MarketBeat recorded 3 mentions for Redhill Biopharma and 0 mentions for Applied Therapeutics. Redhill Biopharma's average media sentiment score of 1.29 beat Applied Therapeutics' score of 0.00 indicating that Redhill Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Redhill Biopharma	Positive
Applied Therapeutics	Neutral

7.2% of Redhill Biopharma shares are owned by institutional investors. Comparatively, 98.3% of Applied Therapeutics shares are owned by institutional investors. 6.8% of Redhill Biopharma shares are owned by company insiders. Comparatively, 1.6% of Applied Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Redhill Biopharma has a beta of 4.98, meaning that its share price is 398% more volatile than the broader market. Comparatively, Applied Therapeutics has a beta of 2.08, meaning that its share price is 108% more volatile than the broader market.

Redhill Biopharma's return on equity of 0.00% beat Applied Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Redhill Biopharma	N/A	N/A	N/A
Applied Therapeutics	N/A	-340.84%	-175.00%

Summary

Redhill Biopharma beats Applied Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Redhill Biopharma compare to Tempest Therapeutics?

Tempest Therapeutics (NASDAQ:TPST) and Redhill Biopharma (NASDAQ:RDHL) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.

In the previous week, Tempest Therapeutics had 1 more articles in the media than Redhill Biopharma. MarketBeat recorded 4 mentions for Tempest Therapeutics and 3 mentions for Redhill Biopharma. Redhill Biopharma's average media sentiment score of 1.29 beat Tempest Therapeutics' score of 0.97 indicating that Redhill Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tempest Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Redhill Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Redhill Biopharma has higher revenue and earnings than Tempest Therapeutics. Tempest Therapeutics is trading at a lower price-to-earnings ratio than Redhill Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tempest Therapeutics	N/A	N/A	-$26.26M	-$6.01	N/A
Redhill Biopharma	$290K	13.28	-$430K	$900.00	0.00

Tempest Therapeutics has a beta of -1.73, suggesting that its share price is 273% less volatile than the broader market. Comparatively, Redhill Biopharma has a beta of 4.98, suggesting that its share price is 398% more volatile than the broader market.

Redhill Biopharma's return on equity of 0.00% beat Tempest Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tempest Therapeutics	N/A	-355.61%	-121.21%
Redhill Biopharma	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tempest Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Redhill Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

22.5% of Tempest Therapeutics shares are held by institutional investors. Comparatively, 7.2% of Redhill Biopharma shares are held by institutional investors. 36.3% of Tempest Therapeutics shares are held by insiders. Comparatively, 6.8% of Redhill Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Redhill Biopharma beats Tempest Therapeutics on 8 of the 12 factors compared between the two stocks.

Get Redhill Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RDHL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RDHL vs. The Competition

Export

Metric	Redhill Biopharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.06M	$3.07B	$6.87B	$12.26B
Dividend Yield	N/A	2.07%	2.67%	9.79%
P/E Ratio	0.00	20.29	27.14	23.64
Price / Sales	13.28	485.19	517.08	89.45
Price / Cash	N/A	27.62	50.54	59.64
Price / Book	0.76	4.13	10.28	6.07
Net Income	-$430K	$65.94M	$3.60B	$331.99M
7 Day Performance	-10.17%	-4.16%	-1.27%	-0.63%
1 Month Performance	-26.37%	-3.76%	-0.37%	-2.00%
1 Year Performance	-62.96%	9.94%	18.30%	13.62%

Redhill Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RDHL Redhill Biopharma	1.77 of 5 stars	$0.63 -5.2%	N/A	-65.4%	$4.06M	$290K	0.00	210	News Coverage Positive News Short Interest Decrease Gap Up
HOWL Werewolf Therapeutics	3.3716 of 5 stars	$0.34 +0.8%	$3.75 +989.8%	-68.8%	$16.60M	$1.88M	N/A	40
CYCN Cyclerion Therapeutics	1.4369 of 5 stars	$3.83 +0.3%	N/A	+15.9%	$16.54M	$2.07M	N/A	30	Positive News
AIMD Ainos	0.464 of 5 stars	$1.90 flat	N/A	-46.2%	$16.20M	$120K	N/A	40
APLT Applied Therapeutics	N/A	$0.10 flat	$1.00 +870.9%	N/A	$15.86M	$1M	N/A	30

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RDHL) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Redhill Biopharma (RDHL) Competitors

RDHL vs. HOWL, CYCN, AIMD, APLT, and TPST

How does Redhill Biopharma compare to Werewolf Therapeutics?

Summary

How does Redhill Biopharma compare to Cyclerion Therapeutics?

Summary

How does Redhill Biopharma compare to Ainos?

Summary

How does Redhill Biopharma compare to Applied Therapeutics?

Summary

How does Redhill Biopharma compare to Tempest Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RDHL vs. The Competition

Redhill Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Redhill Biopharma (RDHL) Competitors

RDHL vs. HOWL, CYCN, AIMD, APLT, and TPST

How does Redhill Biopharma compare to Werewolf Therapeutics?

Which has more volatility & risk, HOWL or RDHL?

Which has higher earnings and valuation, HOWL or RDHL?

Do insiders & institutionals have more ownership in HOWL or RDHL?

Is HOWL or RDHL more profitable?

Do analysts rate HOWL or RDHL?

Does the media favor HOWL or RDHL?

Summary

How does Redhill Biopharma compare to Cyclerion Therapeutics?

Does the media favor CYCN or RDHL?

Which has more risk and volatility, CYCN or RDHL?

Is CYCN or RDHL more profitable?

Do analysts rate CYCN or RDHL?

Do insiders and institutionals have more ownership in CYCN or RDHL?

Which has preferable valuation and earnings, CYCN or RDHL?

Summary

How does Redhill Biopharma compare to Ainos?

Do institutionals & insiders have more ownership in AIMD or RDHL?

Which has stronger earnings & valuation, AIMD or RDHL?

Does the media favor AIMD or RDHL?

Which has more volatility and risk, AIMD or RDHL?

Do analysts rate AIMD or RDHL?

Is AIMD or RDHL more profitable?

Summary

How does Redhill Biopharma compare to Applied Therapeutics?

Which has stronger valuation and earnings, RDHL or APLT?

Do analysts recommend RDHL or APLT?

Does the media prefer RDHL or APLT?

Do insiders and institutionals hold more shares of RDHL or APLT?

Which has more risk and volatility, RDHL or APLT?

Is RDHL or APLT more profitable?

Summary

How does Redhill Biopharma compare to Tempest Therapeutics?

Does the media favor TPST or RDHL?

Which has higher valuation and earnings, TPST or RDHL?

Which has more volatility & risk, TPST or RDHL?

Is TPST or RDHL more profitable?

Do analysts prefer TPST or RDHL?

Do institutionals & insiders hold more shares of TPST or RDHL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RDHL vs. The Competition

Redhill Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools